Pertuzumab

🧮 Dose calculator

Breast cancer (hormonal therapy) · Regimen source: FDA Perjeta · 2.3

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Perjeta · 2.3

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Perjeta · Boxed Warning

  “Embryo-fetal Toxicity: Exposure to PERJETA can cause embryo-fetal death and birth defects.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Perjeta · 8.2

  “Risk Summary There is no information regarding the presence of pertuzumab in human milk, the effects on the breastfed infant or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Perjeta · 8.4

  “The safety and effectiveness of PERJETA have not been established in pediatric patients.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Perjeta · 8.5

  “No overall differences in efficacy of PERJETA were observed in patients aged ≥ 65 and <65 years of age.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Perjeta · 8.3

  “Contraception Females Based on the mechanism of action and animal data, PERJETA can cause embryo-fetal harm when administered during pregnancy.”